|
|
| | L-Aspartic acid, 4-(phenylmethyl) ester, 5′-ester with 5-hydroxy-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide, 2,2,2-trifluoroacetate (1:1) Basic information |
| Product Name: | L-Aspartic acid, 4-(phenylmethyl) ester, 5′-ester with 5-hydroxy-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide, 2,2,2-trifluoroacetate (1:1) | | Synonyms: | L-Aspartic acid, 4-(phenylmethyl) ester, 5′-ester with 5-hydroxy-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide, 2,2,2-trifluoroacetate (1:1);Mizoribine prodrug-2 trifluoroacetate | | CAS: | 2237237-32-8 | | MF: | C20H24N4O9.C2HF3O2 | | MW: | 578.45 | | EINECS: | | | Product Categories: | | | Mol File: | 2237237-32-8.mol |  |
| | L-Aspartic acid, 4-(phenylmethyl) ester, 5′-ester with 5-hydroxy-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide, 2,2,2-trifluoroacetate (1:1) Chemical Properties |
| | L-Aspartic acid, 4-(phenylmethyl) ester, 5′-ester with 5-hydroxy-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide, 2,2,2-trifluoroacetate (1:1) Usage And Synthesis |
| Uses | Mizoribine prodrug-2 trifluoroacetate (compound 20) is a oral active mizoribine (HY-17470) prodrug (amino acid conjugate). Mizoribine prodrug-2 displays a prolonged inhibition of IL-2 production[1]. | | References | [1] Gao LJ, et al. Synthesis of mizoribine prodrugs and their in vivo evaluation as immunosuppressive agents. Bioorg Med Chem Lett. 2023;95:129490. DOI:10.1016/j.bmcl.2023.129490 |
| | L-Aspartic acid, 4-(phenylmethyl) ester, 5′-ester with 5-hydroxy-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide, 2,2,2-trifluoroacetate (1:1) Preparation Products And Raw materials |
|